Inhibition of LOX-1 by statins may relate to upregulation of eNOS

Related Experiment Video

Updated: Aug 4, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy
15:55

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

J L Mehta1, D Y Li, H J Chen

  • 1Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. mehtajl@uams.edu

Biochemical and Biophysical Research Communications
|December 12, 2001
PubMed

Insights

Statins reduce oxidized LDL

Area of Science:

  • Cardiovascular Biology
  • Endothelial Cell Biology
  • Pharmacology

Background:

  • Oxidized low-density lipoprotein (ox-LDL) receptor LOX-1 is implicated in endothelial dysfunction and atherosclerosis.
  • Endothelial nitric oxide synthase (eNOS) expression is diminished in these conditions.
  • Statins are known to have cardioprotective effects.

Purpose of the Study:

  • To investigate the role of LOX-1 in eNOS expression.
  • To determine how simvastatin and atorvastatin modulate the LOX-1/eNOS relationship.
  • To explore potential mechanisms of statin action beyond cholesterol reduction.

Main Methods:

  • Human coronary artery endothelial cells (HCAECs) were treated with ox-LDL.
  • Cells were pretreated with varying concentrations of simvastatin and atorvastatin.
  • Expression of LOX-1 and eNOS, and MAP kinase activation were assessed.

Main Results:

  • Ox-LDL upregulated LOX-1 and downregulated eNOS expression in HCAECs.
  • Simvastatin and atorvastatin reduced ox-LDL-induced LOX-1 upregulation and eNOS downregulation.
  • Higher statin concentrations showed greater efficacy, and both statins attenuated MAP kinase activation.

Conclusions:

  • Statins mitigate the adverse effects of ox-LDL on eNOS expression in HCAECs.
  • Inhibition of LOX-1 and MAP kinase activity may underlie the cardioprotective benefits of statins.
  • These findings suggest a mechanism for statin efficacy independent of lipid-lowering.

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
Allosteric Regulation01:08

Allosteric Regulation

Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...